[HTML][HTML] Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis
…, I Stevanovski, AG Beukers, Z Naing, M Yeang… - Nature …, 2020 - nature.com
Viral whole-genome sequencing (WGS) provides critical insight into the transmission and
evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Long-read …
evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Long-read …
[HTML][HTML] SARS-CoV-2 Omicron BA. 5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral …
…, T Hauser, T Barnes, A Condylios, M Yeang… - …, 2022 - thelancet.com
Background Genetically distinct viral variants of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) have been recorded since January 2020. The introduction of global …
2 (SARS-CoV-2) have been recorded since January 2020. The introduction of global …
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study
…, C Café, J Anlezark, W Rawlinson, M Yeang… - The lancet …, 2021 - thelancet.com
Background Limited empirical evidence exists for the effectiveness of hepatitis C virus (HCV)
treatment-as-prevention. The Surveillance and Treatment of Prisoners with hepatitis C (…
treatment-as-prevention. The Surveillance and Treatment of Prisoners with hepatitis C (…
[HTML][HTML] Emergence and antibody evasion of BQ, BA. 2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level
…, T Hauser, T Barnes, A Condylios, M Yeang… - …, 2023 - thelancet.com
Background The Omicron era of the COVID-19 pandemic commenced at the beginning of
2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and the related …
2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and the related …
[HTML][HTML] Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome capture sequencing
Accumulating evidence supports the high prevalence of co-infections among Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) patients, and their potential to worsen …
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) patients, and their potential to worsen …
[HTML][HTML] SARS Coronavirus-2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays
GJ Walker, Z Naing, A Ospina Stella, M Yeang… - Viruses, 2021 - mdpi.com
Serological testing for SARS-CoV-2-specific antibodies provides important research and
diagnostic information relating to COVID-19 prevalence, incidence and host immune response. …
diagnostic information relating to COVID-19 prevalence, incidence and host immune response. …
[HTML][HTML] Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in point-of-care (POC) testing
…, G Walker, AO Stella, A Aggarwal, M Yeang… - Viruses, 2020 - mdpi.com
Critical to facilitating SARS-CoV-2 point-of-care (POC) testing is assurance that viruses present
in specimens are inactivated onsite prior to processing. Here, we conducted experiments …
in specimens are inactivated onsite prior to processing. Here, we conducted experiments …
Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes
Isolation of the new pandemic virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is essential for diagnostic and research purposes including assessment of novel …
is essential for diagnostic and research purposes including assessment of novel …
Circulation of enterovirus D68 (EV-D68) causing respiratory illness in New South Wales, Australia, between August 2018 and November 2019
The incidence of enterovirus D68 (EV-D68) in New South Wales, Australia, is unknown. As
part of a state-wide surveillance program, enterovirus positive diagnostic specimens were …
part of a state-wide surveillance program, enterovirus positive diagnostic specimens were …
Persistent high‐level shedding of cultivable SARS‐CoV‐2 Delta virus 33 days after onset of COVID‐19 in a hospitalized patient with pneumonia
KW Kim, X Wang, A Adhikari, M Yeang… - Journal of Medical …, 2022 - Wiley Online Library
Dear Editor The viral dynamics of SARS‐CoV‐2 infections with non‐Delta strains has followed
a typical trajectory of viral RNA shedding for a mean duration of 17 days, accompanied by …
a typical trajectory of viral RNA shedding for a mean duration of 17 days, accompanied by …
